innovation policy in cross border perspective€¦ · maastricht forensic institute clinical trial...

25
Innovation Policy in Cross border perspective “Acceleration Agenda in the Euroregion Meus Rhein/ELAT –Triangle” Basel, 22 February 2008 Jean Severijns (Martin Eurlings, Herman Vrehen)

Upload: others

Post on 13-Jul-2020

3 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Innovation Policy in Cross border perspective

“Acceleration Agenda in the Euroregion Meus Rhein/ELAT –Triangle”

Basel, 22 February 2008

Jean Severijns

(Martin Eurlings, Herman Vrehen)

Page 2: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Province of Limburg (NL)

Page 3: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

A Top Technological region within Europe

� Bron: Brainport

Page 4: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

��

��

� ��

��

EU Hall of Fame EU Hall of Fame candidatescandidates

� ??�

Page 5: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

TECHNOLOGY CAMPUS LEUVEN

ELAT / Private R&D Capacity ( DSP ) ELAT / Private R&D Capacity ( DSP )

Ubiwave

Page 6: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Organise cross border communication and commitment !

Page 7: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

2020

From Closed to Open InnovationFrom Closed to Open Innovation

Henry Chessbrough, Harvard

ResearchProjects

BoundaryFirm

DevelopmentResearch

Current Market

NewMarket

NewMarket

Philips DSM/Chemelot

Scheuten Glas

Open innovation examples/principle

Page 8: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Conclusions so far:

•Limburg integral part of Functional Border region•Aiming at highest level in Europe•Similarities open communication and open innovation approachbusiness community – governmental policy

•Respect different parts within cross border triangle/functional region•Cooperation needs to be organized (Role Province!)

Acceleration agendaLimburg

Page 9: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Power clusters in Limburg

High Tech Systems & MaterialsEnergy TechnologyHealth, Life Sciences & LeisureGreenport, Food & Nutrition

Page 10: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

High Tech Systems & Materials

Energy Technology

Health, Life Sciences & Leisure

Greenport, Food & Nutrition

Combine elements of different value chainsis the real challenge, within region and cross border(according to open innovation principle)

Biomedicalmaterials

Healthy food

Solar cluster

Greenhouse of the future

Page 11: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Healthcare - pillarsTopcare - Hospital

R&D -Medical scientific research

Biomedical bus. community

Healthcare

Entrepreneurship and innovation

CardiovasculairOncologyChronical deseasesPsychological health-care

azM-Klinikum cooperationParticle Therapy CentreEuropean Vascular Centre Maastricht-AachenCentre for molecular medicineMaastricht Forensic InstituteClinical Trial CentreToxicogenomicsHealth Science CampusResearch Valorisation Booster

BiomaterialsBiopartnerCentre

Page 12: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Klinikum Aachen

AZM Maastricht

Parc Hoogveld

“Orbis” Hospital of the future

Page 13: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

June 8, 2004 Signing Co-operation agreement

Page 14: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

MUMC+

30715

25.768381.000

7.6

4946

Medical departmentsClinical beds

Clinical admissionsOutpatient visits

Hospital stay (days)

Employees

MUKA

34149343.000121.0007.9

6.249

Page 15: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Essential points agreement 2004

• European Centre for state-of-the-art medicine and research

• Benefit from each other‘s knowledge

• Complementary health care

• Synergy in use of resources

• Building European Centers of Reference

• Joint leadership of medical departments

• Synchronisation of research and teaching

• Network medical education and specialist training

Page 16: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Current Activities

� Feasibility study for cardiovascular merge betweenMaastricht and Aachen: Vascular Surgery, Cardiac Surgery, Cardiology

� Business plan to develop Cardiovascular Center of Excellence Maastricht-Aachen

� Venue: new building

Page 17: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials
Page 18: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Feasibility study (from December 2007)

� Assessment of the local, regional and national market- and competitive environment;

� Point out the strategic options of UKA and MUMC+;

� Identification and assessment of potential for synergies in patient care, especially top-referal healthcare;

� Identification and assessment of legal and structural options;

� Preparation of a time schedule, project- and action plan

Page 19: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials
Page 20: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Stent placement

The drug eluting stent represents the first great break-through of a combination product of biomedical materials & drugs

Source: Endeavor III clinical trials, 9 month follow-up data presented at TCT 2005; Herald-Sun 24 Feb. 2006

Cardiovascular intervention

Situation before and after placement

EXAMPLES OF RESEARCH TOPICS

Page 21: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Stents have radically changed medical treatment;next generation stents will be worked on

Old Therapy:Open heart surgery

New Therapy:Using stent

Future Therapy:Resorbable stent

Source: DSM

EXAMPLES OF RESEARCH TOPICS

Page 22: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

A strong public-private partnership is committed to further strengthen the position of the Netherlands in biomedical materials

Total budget 90 m€ for a 5 year program

FOUNDING PRINCIPLES AND PARTNERS

Page 23: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

We invite:Health care oriented (functional/cross border) serious and enthusiastic regions, to join forces!

Thank you for your attention !

Province of Limburg (NL)[email protected]

Page 24: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials

Feasibility study (from December 2007)

� Assessment of the local, regional and national market- and competitive environment;

� Point out the strategic options of UKA and MUMC+;

� Identification and assessment of potential for synergies in patient care, especially top-referal healthcare;

� Identification and assessment of legal and structural options;

� Preparation of a time schedule, project- and action plan

Page 25: Innovation Policy in Cross border perspective€¦ · Maastricht Forensic Institute Clinical Trial Centre Toxicogenomics Health Science Campus Research Valorisation Booster Biomaterials